Evidence map›Paper›PMID 40553397›Full record

ArticleMolecular biology reports2025

UBE3C promotes pancreatic ductal adenocarcinoma progression by catalysing p53 ubiquitination.

Yang Shi, Jiaxi Wang, Qian Cheng, Shuaihui Wu, Xian Qin, Zhiyong Yang

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Ubiquitination and NOncology letters · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yang Shi *Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, 430071, China.
Jiaxi Wang *Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, 430071, China.
Qian Cheng *Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, 430071, China.
Shuaihui WuDepartment of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, 430071, China.
Xian QinDepartment of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, 430071, China. paulqqqqq@hotmail.com.
Zhiyong YangDepartment of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, 430071, China. yangzhiyong@whu.edu.cn.

Funding

the Natural Science Foundation of Hubei Province 2023AFB169the talent introduction project of Zhongnan Hospital of Wuhan University 20190101
6 · The paper itself

Abstract

backgroundPancreatic ductal adenocarcinoma (PDAC) is among the deadliest malignancies worldwide. Ubiquitination is a biological process that regulates the degradation of proteins. Previous studies have indicated that ubiquitin ligase E3C (UBE3C) has procarcinogenic properties in various tumours. Nevertheless, the detailed role of UBE3C in PDAC is still unknown. METHODS AND

resultsBioinformatics analyses of UBE3C were performed, and we found that UBE3C expression was increased in PDAC cells and indicates a poorer clinical prognosis. Moreover, a significant positive correlation existed between UBE3C expression and the number of CD4

conclusionsOur results clarify the importance of UBE3C in PDAC and indicate that the UBE3C-p53 axis may be a novel therapeutic target for PDAC. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsTumor Suppressor Protein p53Ubiquitin-Protein LigasesAnimalsApoptosisCell Line, TumorCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMiddle AgedPrognosisTP53 protein, humanTumor Suppressor Protein p53UBE3C protein, humanUbiquitin-Protein Ligasesp53Pancreatic ductal adenocarcinomaUBE3CUbiquitination

Identifiers

PMID40553397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.